~~<i id='746CB69E07'><strike id='746CB69E07'><tt id='746CB69E07'><pre id='746CB69E07'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：explore 2025-10-01 17:07:29 Page View：4459

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Problems with a popular proposal to regulate AI in health care
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts

explore

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Covid’s new normal has set in amid another rise in cases

Colorizedscanningelectronmicrographofanapoptoticcell(pink)heavilyinfectedwithSARS-COV-2virusparticle

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

FDA panel to weigh safety of artificial wombs for preterm births

AdobeTheartificialwomb,adeviceaimingtosaveinfantsbornwaytoosoon,isinchingclosertobeingtestedinhumans